There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Molnupiravir (EIDD-2801) is an antiviral medication that inhibits the replication of certain RNA viruses. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1]. Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2]. It has recently been tested in COVID-19. 1600mg daily dose of molnupiravir is safe and tolerable, without any serious adverse events up to 5.5 days, and significantly lower time to clearance (RNA negative) with molnupiravir 800mg twice daily. The study also showed a significant reduction in the risk of hospital admission or death by 50% with the treatment of molnupiravir[3].
Molnupiravir 细胞实验
Cell Line
Concentration
Treated Time
Description
References
A549-hACE2 cells
2.8 μM
48 hours
Evaluate the inhibitory effect of Molnupiravir on SARS-CoV-2 nLUC replication, showing dose-dependent antiviral effects
Sci Transl Med. 2022 May 4;14(643):eabm3410
Calu-3 cells
10 μM
48 hours
To validate the antiviral activity of Molnupiravir against SARS-CoV-2 in Calu-3 cells, results showed significant antiviral effects.
Nature. 2022 Apr;604(7904):134-140
human airway organoids (hAOs)
10 μM
Validate the antiviral activity of Molnupiravir in hAOs. Results showed that 10 μM Molnupiravir reduced viral RNA levels by >90%.
Cell Res. 2022 Mar;32(3):322-324
human lung epithelial Calu-3 cells
1 μM, 10 μM
48 hours
Evaluate the antiviral activity of Molnupiravir against the Omicron variant. Results showed that 1 μM Molnupiravir reduced viral RNA by 70.4%, and complete inhibition was achieved at 10 μM and higher concentrations.
Cell Res. 2022 Mar;32(3):322-324
Molnupiravir 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Syrian Gold hamsters
SARS-CoV-2 infection model
Oral
250 mg/kg
Twice daily for 6 days
Evaluate the inhibitory effect of drug combination on SARS-CoV-2 replication, results showed combination treatment significantly reduced viral load
iScience. 2022 May 20;25(5):104293.
Ferrets
Upper respiratory infection model
Oral
5 mg/kg
Twice daily for 4 days
Assess the therapeutic effect of EIDD-1931 on upper respiratory infection, showing significant reduction in viral shedding and prevention of transmission.
Nat Commun. 2022 Jul 29;13(1):4416.
Sprague-Dawley rats
Pregnant rat model
Intravenous injection
100 mg/kg
Single dose
To investigate the pharmacokinetics and placental transfer of EIDD-1931 in pregnant rats. Results showed that EIDD-1931 rapidly crosses the placental barrier into the fetus, and its concentration in the fetus was higher than the IC50 for SARS-CoV-2.
EBioMedicine. 2023 Sep;95:104748
C57BL/6 mice
SARS-CoV infection model
Oral
50, 150, 500 mg/kg
Every 12 hours until the end of the study
Evaluate prophylactic and therapeutic efficacy of EIDD-2801 against SARS-CoV, significantly reduced weight loss and lung hemorrhage, decreased virus titer
Sci Transl Med. 2020 Apr 29;12(541):eabb5883
Ferrets
SARS-CoV-2 infection model
Oral gavage
5 mg/kg or 15 mg/kg
Twice daily, continued until four days after infection
To evaluate the therapeutic effect of oral MK-4482/EIDD-2801 on SARS-CoV-2 infection in ferrets, results showed significant reduction in upper respiratory tract viral load and complete suppression of virus transmission to untreated contact animals.
Nat Microbiol. 2021 Jan;6(1):11-18
Ferrets
Upper respiratory infection model
Oral
5 mg/kg
Every 12 hours for 4 days
Assess the therapeutic effect of Molnupiravir on upper respiratory infection, showing significant reduction in viral shedding and prevention of transmission.
Nat Commun. 2022 Jul 29;13(1):4416
Syrian hamsters
SARS-CoV-2 infection model
Oral gavage
250 mg/kg
Dosed every 12 hours for 3 days
To assess the inhibitory effect of MK-4482 on SARS-CoV-2 replication, results showed that MK-4482 significantly reduced viral lung loads and pathology
Nat Commun. 2021 Apr 16;12(1):2295
BALB/C mice
SARS-CoV-2 Beta variant infection model
Oral
50 mg/kg and 150 mg/kg
Twice daily for 2 days
To evaluate the antiviral efficacy of Molnupiravir in a mouse model of SARS-CoV-2 Beta variant infection, results showed significant reduction in viral titers and lung inflammation.
Nature. 2022 Apr;604(7904):134-140
Balb/c mice
HCoV-OC43 infection model
Oral
200 mpk
Once daily for 4 days
Evaluate the therapeutic efficacy of Molnupiravir against HCoV-OC43 infection, showing significant reduction in viral load.
Signal Transduct Target Ther. 2023 Sep 22;8(1):360
搜索
HazMat Fee +
